Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation<blockquote>随着 FDA 批准其 Lomecel-B 用于罕见儿科疾病名称,Longeveron 在上市前交易中继续攀升超过 50%</blockquote>
Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare p